PMA device
VISCO-3
Seikagaku Corp. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Dec 21, 2015, newest Dec 21, 2015Knee osteoarthritis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
1
Naming "VISCO-3"
MAUDE reports
9
Brand "VISCO-3", since 2015
PubMed studies
0
Mentioning "VISCO-3"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VISCO-3
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- VISCO-3PMA supplement
P980044-S027 · Decided Dec 21, 2015 · 166 days after receipt · Panel Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "VISCO-3", any status and sponsor, newest update first.
- Regenerative Medicine for Joint Hypermobility and InstabilityNot yet recruiting
Manhattan Pain Medicine, PLLCAcademic, hospital or other
NCT07688096 · 100 participants (planned) · Start Jan 15, 2027 · Primary completion Dec 31, 2027
Device: Visco-3 Sodium Hyaluronate Viscosupplementation · For: Ehlers-Danlos Syndrome Hypermobility Type (hEDS); Ehlers-Danlos Syndrome (EDS); Joint Hypermobility and 8 more
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VISCO-3", and for the whole product code for context.
This brand
9 reports: 2 malfunction, 7 injury, 0 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- VISCO-3Injury
9612392-2026-00005 · Received Sep 2, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available
- VISCO-3Injury
0001822565-2025-00764 · Received Mar 26, 2025
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
- VISCO-3Injury
0001822565-2024-03403 · Received Oct 28, 2024
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "VISCO-3"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.